Cargando…

HKI-272 contributes to gemcitabine-mediated anti-proliferative and anti-metastatic effects through EGFR suppression in gallbladder cancer

Gallbladder cancer (GBC) is a rare malignancy of the biliary system and characterized by early metastasis and poor prognosis. To date, no efficient treatment is available for GBC patients. Based on the data from cBioPortal, TIMER, and GDSC, we performed an unbiased screening with 25 candidate compou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yang, Xuli, Chen, Tao, Hu, Jie, Wang, Jian, Yang, Dong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596964/ https://www.ncbi.nlm.nih.gov/pubmed/36321135 http://dx.doi.org/10.1016/j.omto.2022.10.004

Ejemplares similares

Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer
por: Chow, L W-C, et al.
Publicado: (2013)

Anti-proliferative activity of the quassinoid NBT-272 in childhood medulloblastoma cells
por: von Bueren, André O, et al.
Publicado: (2007)

Complete genome sequence of Beutenbergia cavernae type strain (HKI 0122(T))
por: Land, Miriam, et al.
Publicado: (2009)

Fatal gemcitabine-induced pulmonary toxicity in metastatic gallbladder adenocarcinoma
por: Galvão, Flávio Henrique Ferreira, et al.
Publicado: (2009)

272 Gender and Different Prevalence in Asthma Treatment With Anti-IGE (Omalizumab)
por: Patella, Vincenzo, et al.
Publicado: (2012)

ODP272 ROUNDUP IS AN IMPORTANT DISRUPTOR THAT CAUSES PROLIFERATIVE EFFECTS ON NORMAL AND ON CANCER THYROID CELLS
por: Ward, Laura Sterian, et al.
Publicado: (2022)

Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas
por: Pignochino, Ymera, et al.
Publicado: (2010)

Complete Resolution of Metastatic Gallbladder Cancer after Standard Gemcitabine-Cisplatin Combination Therapy
por: Rho, Young Soo, et al.
Publicado: (2015)

Health Tract, No. 272: Typhoid
Publicado: (1868)

Role of Maintenance Gemcitabine in Advanced Carcinoma Gallbladder
por: Sharma, Manish, et al.
Publicado: (2020)

Health Tract, No. 272: Eating Mathematically
Publicado: (1868)

Anti-proliferative Activity of T-bet
por: Oh, Yeon Ji, et al.
Publicado: (2015)

Current concepts of anti-EGFR targeting in metastatic colorectal cancer
por: Doleschal, Bernhard, et al.
Publicado: (2022)

Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response
por: Liu, X., et al.
Publicado: (2015)

Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance
por: Li, Qing-Hai, et al.
Publicado: (2020)

The Anti-Angiogenic and Anti-Proliferative Activity of Methyl Hydroxychalcone
por: Sahib, Hayder B
Publicado: (2022)

Epigenetic activation of the elongator complex sensitizes gallbladder cancer to gemcitabine therapy
por: Xu, Sunwang, et al.
Publicado: (2021)

Dual Anti-Metastatic and Anti-Proliferative Activity Assessment of Two Probiotics on HeLa and HT-29 Cell Lines
por: Nouri, Zahra, et al.
Publicado: (2016)

Anti-metastatic and anti-proliferative activity of eugenol against triple negative and HER2 positive breast cancer cells
por: Abdullah, Mashan L., et al.
Publicado: (2018)

Anti-Proliferative, Anti-Angiogenic and Safety Profiles of Novel HDAC Inhibitors for the Treatment of Metastatic Castration-Resistant Prostate Cancer
por: Rana, Zohaib, et al.
Publicado: (2021)

Prediction of response to anti-EGFR antibodies in metastatic colorectal cancer: looking beyond EGFR inhibition
por: Ottaiano, Alessandro, et al.
Publicado: (2013)

27.2 THE DOPAMINE MOTIVE SYSTEM IN ADDICTION
por: Volkow, Nora
Publicado: (2018)

Molecular determinants of anti-EGFR sensitivity and resistance in metastatic colorectal cancer
por: Di Fiore, F, et al.
Publicado: (2010)

Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality?
por: Dell’Aquila, Emanuela, et al.
Publicado: (2020)

Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer
por: Ciardiello, Davide, et al.
Publicado: (2021)

Anti-proliferative activity of silver nanoparticles
por: AshaRani, PV, et al.
Publicado: (2009)

EGFR monoclonal antibody panitumumab inhibits chronic proliferative cholangitis by downregulating EGFR
por: Liu, San-Hu, et al.
Publicado: (2019)

Anti-proliferative and Anti-metastatic Potential of Curcumin Analogue, Pentagamavunon-1 (PGV-1), Toward Highly Metastatic Breast Cancer Cells in Correlation with ROS Generation
por: Meiyanto, Edy, et al.
Publicado: (2019)

Anti-Metastatic Activity of an Anti-EGFR Monoclonal Antibody against Metastatic Colorectal Cancer with KRAS p.G13D Mutation
por: Ohishi, Tomokazu, et al.
Publicado: (2020)

The Triterpenoids from Munronia pinnata and Their Anti-Proliferative Effects
por: Yang, Xuerong, et al.
Publicado: (2023)

The anti-dysenteric drug fraxetin enhances anti-tumor efficacy of gemcitabine and suppresses pancreatic cancer development by antagonizing STAT3 activation
por: Guo, Yangyang, et al.
Publicado: (2021)

Polish Natural Bee Honeys Are Anti-Proliferative and Anti-Metastatic Agents in Human Glioblastoma multiforme U87MG Cell Line
por: Moskwa, Justyna, et al.
Publicado: (2014)

Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer
por: Graeven, U, et al.
Publicado: (2006)

aPKCι promotes gallbladder cancer tumorigenesis and gemcitabine resistance by competing with Nrf2 for binding to Keap1
por: Tian, Li, et al.
Publicado: (2019)

Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer
por: Fakih, M., et al.
Publicado: (2010)

KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies
por: Soulières, D., et al.
Publicado: (2010)

Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?
por: Derangère, Valentin, et al.
Publicado: (2016)

An Update on the Role of Anti-EGFR in the Treatment of Older Patients with Metastatic Colorectal Cancer
por: Rosati, Gerardo, et al.
Publicado: (2022)

RF11 | PSAT272 Suppressive Tumor Immune Microenvironment is Associated with Aggressive Differentiated Thyroid Cancer
por: Kotwal, Anupam, et al.
Publicado: (2022)

Phase II study of gemcitabine, oxaliplatin in combination with panitumumab in KRAS wild-type unresectable or metastatic biliary tract and gallbladder cancer
por: Hezel, A F, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_1ossba01hr4ln2mvalpcg35gjt